On December 16th, Jinshi Data News, the company signed an authorization license with SteinCares for the production, supply, and commercialization of the protocol, granting Stein the exclusive commercialization rights for the company’s BAT2306 (Sikuchenyou monoclonal antibody) injection solution in the Brazilian and other Latin American markets. The transaction amount is up to a maximum of $8 million, including a $1.2 million down payment, a cumulative milestone payment of no more than $6.8 million, and a double-digit percentage of net sales as revenue sharing.
Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments carry high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to
Disclaimer.